DuPont Launches AmberChrom XT SL Chromatography Resins to Streamline Biopharmaceutical Manufacturing

Key Takeaways

• DuPont launched AmberChrom XT20 SL and XT30 SL chromatography resins that eliminate the resin hydration step in biopharmaceutical manufacturing
• The new pre-slurried resins specifically target oligonucleotide and peptide therapeutic purification, addressing a rapidly growing market segment
• This technology advancement could reduce manufacturing time and costs for companies developing RNA-based therapies and peptide drugs

---

DuPont Expands Bioprocessing Portfolio with Ready-to-Use Chromatography Solutions

DuPont (NYSE: DD) announced on April 14, 2026, the commercial launch of its DuPont™ AmberChrom™ XT20 SL and XT30 SL chromatography resins, marking a significant advancement in downstream purification technology for biopharmaceutical manufacturers. The new products are specifically designed to streamline workflows for oligonucleotide and peptide therapeutic production.

Addressing Critical Manufacturing Bottlenecks

The pharmaceutical industry has witnessed explosive growth in oligonucleotide therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNAs (mRNAs). Similarly, peptide-based drugs continue to gain prominence due to their specificity and reduced side effect profiles. However, purification processes for these complex molecules often present manufacturing challenges.

Traditional chromatography resins require a time-consuming hydration step before use, creating bottlenecks in production schedules. DuPont’s new pre-slurried formulations eliminate this requirement, potentially reducing processing time and labor costs while maintaining purification quality standards.

Market Impact and Industry Implications

The global oligonucleotide therapeutics market is projected to reach significant growth over the next decade, driven by advances in RNA interference technology and personalized medicine applications. Manufacturing efficiency improvements like those offered by AmberChrom XT SL resins could help companies scale production more effectively to meet increasing demand.

For contract development and manufacturing organizations (CDMOs) and pharmaceutical companies, streamlined purification processes translate to improved operational efficiency and potentially faster time-to-market for critical therapeutics.

Technical Specifications and Applications

The XT20 SL and XT30 SL variants are engineered to handle the unique purification challenges associated with oligonucleotides and peptides, including their sensitivity to processing conditions and the need for high-purity final products. The ready-to-use format reduces preparation variability and standardizes manufacturing protocols across different production sites.

---

Frequently Asked Questions

How do these new resins improve biopharmaceutical manufacturing?

The pre-slurried AmberChrom XT SL resins eliminate the time-consuming resin hydration step, reducing processing time and labor costs while maintaining high purification standards for oligonucleotide and peptide therapeutics.

When will the AmberChrom XT SL resins be available to manufacturers?

DuPont announced the commercial launch on April 14, 2026, indicating the products are now available for biopharmaceutical manufacturers and CDMOs to integrate into their purification workflows.

What types of drugs benefit from this chromatography technology?

The AmberChrom XT SL resins are specifically designed for oligonucleotide therapeutics (including ASOs, siRNAs, and mRNAs) and peptide drugs, which represent rapidly growing segments in the pharmaceutical industry.